Clinical Trials

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

46 enrolled

CNS

Meningeal Carcinomatosis

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

63 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

60 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07314216 2026-01-06

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05465343 2025-12-19

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Phase 2 Completed

24 enrolled

CNS

Brain Neoplasms

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

100 enrolled

NSCLC

NCT07193160 2025-09-25

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06962865 2025-07-16

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04671303 2025-05-11

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Phase 2 Completed

36 enrolled

Lung Neoplasms

NCT03452592 2025-04-03

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Phase 2 Terminated

220 enrolled

Advanced NSCLC Patients With T790M

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung

NCT05379803 2024-09-19

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

NCT06585644 2024-09-05

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

44 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06394674 2024-07-26

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06483672 2024-07-03

LungBrain001

27 enrolled

Adenocarcinoma of Lung, Brain Neoplasms

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

91 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06339242 2024-04-01

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

NSCLC

NCT06319950 2024-03-20

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

255 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06192849 2024-01-05

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05813522 2023-04-14

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05445310 2023-02-16

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

114 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04895930 2023-01-06

FOCUS-A

Carcinoma, Non-Small-Cell Lung

NCT05548348 2022-09-21

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Carcinoma, Non-Small-Cell Lung

NCT05334277 2022-08-31

FOCUS-C

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05503667 2022-08-17

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

96 enrolled

Adenocarcinoma of Lung

NCT05255406 2022-08-04

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05165355 2022-01-18

ATHEM

90 enrolled

NSCLC

NCT04982900 2021-10-05

TERMGGO

138 enrolled

Multiple Primary Lung Cancers

NCT04970693 2021-07-21

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04965831 2021-07-16

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)